a Randomized, Double-blind, Placebo-controlled Trial, IFM 01/01
-- Oral Presentation - 5:45 p.m.: Melphalan-Prednisone-Thalidomide to
Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled
Randomized Phase 3 Trial (Abstract #78).
Date / Time / Location: December 10, 2007; 7:30-9:00 a.m.; Rooms C303-
C305, Georgia World Congress Center
Session: Myeloma: Frontline Therapy in Newly Diagnosed Multiple Myeloma
-- Oral Presentation - 7:45 a.m.: A Phase II Study of Velcade,
Cyclophosphamide, Thalidomide and Dexamethasone as First-Line Therapy
for Multiple Myeloma (Abstract #188).
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C306- C308, Georgia World Congress Center
Session: Autologous Transplantation for Myeloma: Induction,
Mobilization, and Biologic Correlates
-- Oral Presentation - 2:00 p.m.: Incorporation of Thalidomide into Up-
Front Double Autologous Stem Cell Transplantation (ASCT) for Multiple
Myeloma Improves Outcome in Comparison with Double ASCT without
Thalidomide. Analysis of Baseline Factors Predictive of Outcome
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C303- C305, Georgia World Congress Center
Session: Myeloma: Maintenance, Consolidation and Bone Disease in
-- Oral Presentation - 1:45 p.m.: Consolidation with Bortezomib,
Thalidomide, and Dexamethasone Induces Molecular Remissions in
Autografted Multiple Myeloma Patients (Abstract #530).
-- Oral Presentation - 2:15 p.m.: Thalidomide-Dexamethasone vs
Interferon-Dexamethasone as Maintenance Treatment after ThaDD induction
for Multiple Myeloma: Final Analysis of a Prospective, Randomized
Study (Abstract #532).
|SOURCE Pharmion Corporation|
Copyright©2007 PR Newswire.
All rights reserved